An observational study in Atherosclerosis, sponsored by IRCCS Policlinico S. Donato. Recruiting at 1 site in Italy. Per ClinicalTrials.gov, last updated 2026-04-07.
Sponsored by IRCCS Policlinico S. Donato · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 81 studies in Atherosclerosis with a site in Italy — 12 open to participants now, 22 under way, 10 of them phase 3. Atherosclerosis · Italy.
Among the 81 studies in Atherosclerosis with a site in Italy, this one is the 28th largest by planned enrollment of the 29 observational ones that give a count, is one of 2 that started in 2023, is one of 30 observational ones, reaches primary completion later than 7 of the 21 other live ones, and was the 65th registered.
1,519 studies on the registry are indexed under Atherosclerosis; 226 are open to participants now.
Browse Atherosclerosis studies →12 of the 81 studies in Atherosclerosis with a site in Italy are open now. Recruiting first, the newest first:
Fondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi) · Sites in Italy, France, Netherlands and 1 more country
Ages 12+
Fondazione Ricerca e Innovazione Cardiovascolare ETS · Sites in Italy
I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio · Sites in Italy
Ages 40–70 · Healthy volunteers
Eli Lilly and Company · Sites in Italy, United States, Argentina and 25 more countries
Ages 18+
AstraZeneca · Sites in Italy, United States, Argentina and 33 more countries
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 164 Atherosclerosis studies recruiting now, 86 (52%) set no upper age limit and 34 (21%) stop at 75 or younger; 16 take children under 18; 35 take healthy volunteers.
This study: all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
81 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 9 · Phase 3 20 · Phase 4 6
First in 1996; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 12 is below the median of 250 across 526 observational studies indexed under Atherosclerosis.
Median enrollment 423 across the 51 interventional studies, 312 across the 29 observational. Of the 43 that completed or were terminated, 15 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 81 have an industry lead sponsor. The 10 most frequent:
IRCCS Policlinico S. Donato is the lead sponsor of 105 studies on the registry; 53 are open to participants now.
IRCCS Policlinico S. Donato has 3 studies filed under Atherosclerosis — fewer than ten, so there is no comparison to draw.
5 of the studies in Atherosclerosis with a site in Italy that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05202509Phase 3NewAmsterdam PharmaCardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease | 2026-11 |
| NCT05030428Phase 3Novartis PharmaceuticalsStudy of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease | 2027-05-10 |
| NCT06230406IRCCS Policlinico S. DonatoT-Mem GEne in Atherosclerosis | 2026-12 |
| NCT07352111I.R.C.C.S Ospedale Galeazzi-Sant'AmbrogioHigh-risk Coronary Atherosclerosis in Subjects With Family History of Myocardial Infarction | 2026-12-31 |
| NCT07447648Fondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi)Assessing the Impact of Intensification of Lipid Lowering Therapy With Guidelines-based Evinacumab Administration on Coronary Plaque Volumes Measured by Coronary Computed Tomography Angiography (CCTA) in Patients With Homozygous Familial Hypercholesterolemia (HoFH) | 2027-09 |
Add all 5 to your calendar (.ics) → With an account.
Among the 81 studies in Atherosclerosis with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Atherosclerosis is the main cause of cardiovascular diseases and is characterized by the progressive accumulation of lipids and inflammatory cells such as macrophages and lymphocytes within the vessel wall of large and medium-sized arteries, forming the so-called "atherosclerotic plaques". The formation process of these lesions is different depending on the age, genetics and physiological state of the individual affected. Furthermore, behavioral factors and the lifestyle of each individual play a key role, which can lead to the presence of a series of pro-atherosclerotic pathologies and risk factors, such as in particular systemic arterial hypertension, dyslipidemia, hyperglycemia and cigarette smoking. However, the precise molecular mechanisms underlying this pathogenetic process are still under investigation.
The results of a study conducted in the past in collaboration between the U.O. have recently been published. of Vascular Surgery and the laboratory of Dr. I. Zucchi of the Institute of Biomedical Technologies of the CNR of Milan Segrate (Protocol GEMMA NUOVA, 16/int/2016), which describes that the overexpression of a newly identified gene (TMEM230) it may have a role in the formation of atherosclerotic vascular disorders, but it is still unclear how the expression of this gene is modulated in vivo.
Knowledge of these factors would increase the knowledge of the molecular mechanisms underlying atherosclerosis and could represent a possible target for prevention and targeted pharmacological treatment, with consequent potential reduction in disability or mortality from cardiovascular diseases.
The proposed study aims to analyze, in patients suffering from vascular pathologies, the modulation of the expression of the TMEM230 gene, identified in the laboratory of Dr. I. Zucchi of the Institute of Biomedical Technologies (CNR of Milan Segrate), and its role in the molecular mechanisms of atherosclerosis.
This collaboration aims to collect a series of patients with different vascular pathologies.
This is a transversal genetic study, which involves the analysis of approximately 12 samples of vascular tissue of various types coming from the intraoperative removal of material that is normally disposed of in appropriate containers for biological waste. In particular, the vascular samples will be represented by: varicose veins (for varicectomies), carotid/femoral plaque (for thromboendarterectomy), artery wall (for aneurysmectomy/limb amputations). Alongside the collection of these samples, 5 ml of venous blood will also be collected from a peripheral venous access already positioned on the patient for the surgical procedure, regardless of the study in question.
The study requires that the samples taken be temporarily stored in order to guarantee correct analysis, according to the methods described below, and destroyed at the end of the study.
All patients coming to the Operative Unit of Vascular Surgery at IRCCS Policlinico San Donato, needing open surgical intervention for arterial and/or venous pathologies
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
collection of vascular samples from surgery and blood samples
T-Mem expression
Analysis of the gene expression profile in different vascular and blood samples.
Time frame: through study completion, an average of 2 years
3D organoids
Generation of pathological 3D organoids from patient vascular samples, to study the modulation of gene expression, also using sequencing techniques.
Time frame: through study completion, an average of 2 years
Plan to share: Undecided
Started Sep 2023 (actual). Primary completion is estimated for Dec 2026, 39 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.